Compare Natera Inc. Common Stock (NTRA) vs Teladoc Health Inc (TDOC) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Teladoc Health trades at $6.00, showing modest daily gains but remains near multi-year lows with bearish technical signals. The company maintains strong revenue around $2.5B annually but continues posting net losses, though improving from historical levels. Recent management changes and ongoing BetterHelp challenges create uncertainty, while the Integrated Care segment shows promise. Valuation metrics appear attractive with P/S of 0.43 and P/B of 0.83, suggesting potential undervaluation if profitability improves.

The stock presents a high-risk opportunity with significant upside potential if management can stabilize operations and achieve profitability. Analyst consensus targets $8.83 (47% upside) with no sell ratings, but execution risks remain elevated. Key catalysts include successful CFO transition, BetterHelp stabilization, and Integrated Care margin expansion. Investors should weigh the attractive valuation against persistent losses and competitive pressures in telehealth.